Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser zaps skin amyloid deposits in rare itching disorder

NCT ID NCT07815132

Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers at Tanta University are testing whether fractional CO2 laser can reduce skin amyloid deposits and itching in people with primary cutaneous amyloidosis. The trial enrolls 22 adults with confirmed disease who have not used other treatments for at least six months. Participants are randomly assigned to receive three laser sessions four weeks apart or no laser treatment. The team measures changes in an amyloidosis severity score, skin appearance under dermoscopy and electron microscopy, itching, satisfaction, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fractional CO2 laser therapy
What this could lead to
If it works, fractional CO2 laser could offer a non-drug way to reduce skin amyloid deposits and itching in people with primary cutaneous amyloidosis.
What could go wrong
This is a small, single-center study of 22 people, so results may not apply broadly. Laser treatment can cause pain, redness, blistering, or pigment changes, and the condition may return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Sep 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older, of either sex. Patients with a clinical and histopathologically confirmed diagnosis of primary cutaneous amyloidosis. No systemic or topical treatment for primary cutaneous amyloidosis for at least 6 months before enrollment. Ability and willingness to comply with all study procedures and follow-up visits. Provision of written informed consent before participation. Exclusion Criteria: * Patients with systemic amyloidosis. Patients with a history of keloid formation. Patients with coagulation disorders. Pregnant or lactating women. Patients with other relevant dermatological diseases that may interfere with study assessment. Patients with Fitzpatrick skin types V or VI. Patients with diabetes mellitus or renal or hepatic disease. Patients with photosensitivity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyloid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease amyloidosis primary cutaneous amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyloid Fractional LASER

Contacts and locations

Locations

  • Tanta University Hospitals

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.